To access this element change to forms mode OFF
Grant Award View - GA289064
The Cannabidiol First-Episode Psychosis Study
GA ID:
GA289064
Agency:
Department of Health and Aged Care
Approval Date:
9-Dec-2022
Publish Date:
20-Mar-2023
Category:
Medical Research
Grant Term:
1-Feb-2023 to 31-Jan-2026
Value (AUD):
$2,604,231.90
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 22/23 1.1 Health Policy Research and Analysis
Grant Program:
Medical Research Future Fund
Grant Activity:
The Cannabidiol First-Episode Psychosis Study
Purpose:
Two thirds of young people with psychosis do not respond to antipsychotic medication during initial treatment and therefore are switched to a second or third antipsychotic with a similar mechanism of action. Since cannabidiol, a non-intoxicating part of the Cannabis plant, does not appear to depend on the same mechanism, this agent may represent a new class of treatment psychosis when treatment with conventional antipsychotic medication as sole antipsychotic agent has a low success rate.
GO ID:
GO Title:
MRFF 2021 Clinical Trials Activity Grant Opportunity
Internal Reference ID:
2022/MRF2018748
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, SA, WA
Postcode:
Multiple
Country:
AUSTRALIA